-The Hindu Current price negotiated through bulk orders may not be replicable: Finance Secy The first lot of vaccines were procured by the Centre using PM CARES funds at a higher rate than the subsequent rounds paid for by budgetary allocations, The Hindu has learnt from the response to a Right to Information request by a transparency activist. The Health Ministry response said that the initial 5.6 crore doses of Covishield were bought...

-Moneycontrol.com The TMC increased its tally of seats won, by two to 213 and its vote-share galloped to 48 percent. This victory was achieved against the BJP, which is believed to have the best election machinery in India The outcome of the West Bengal assembly polls has many firsts. The average winning margin of all the candidates in this election stands out at a record 26,964 votes, while the same for Trinamool...

-The Indian Express A waiver on IP protections would mean pharmaceutical firms and vaccine makers across the world can learn how to make these vaccines without fear of lawsuits from companies that originally developed them. In a move that could potentially help increase production of Covid-19 vaccines around the world, the United States on Wednesday announced its support for waiving intellectual property (IP) protections for these vaccines. Subsequently, the European Union (EU) agreed...

-TheIndiaForum.in Aprajita Sarcar is a postdoctoral researcher at the Centre de Sciences Humaines, New Delhi. She works on histories of reproductive technology, population control and their links to urbanisation in India. India’s family planning programme advertised the small middle-class family as a means to develop the nation. But its top-down approach meant that sterilisations became the default contraceptive option for poor and working class women. This legacy persists. In a letter to the...

-The Hindu Business Line It’s only an open-ended deal with co-developer Bharat Biotech, says top source The Indian Council of Medical Research (ICMR) is willing to share the know-how to produce the indigenously-developed Covid-19 vaccine, Covaxin, with any company as the contract with co-developer Bharat Biotech is not close-ended. Currently, Bharat Biotech has the sole licence to manufacture Covaxin, which it developed in collaboration with scientists from ICMR’s Pune-based National Institute of Virology...